Day One

Wednesday May 25, 2022

Day Two

Thursday May 26, 2022

Day Two Agenda

Want to see the agenda, speaker faculty and more all in one place? Download the 2022 full Event Guide.

8:30 am Morning Networking Coffee

8:50 am Chair’s Opening Remarks

  • Andrew Geall Co-founder & Chief Development Officer, Replicate Bioscience

Innovating Immunotherapy Approaches through Next Generation RNA Therapeutics

9:00 am mRNA 2.0 Immunotherapy for Cancer

  • Yusuf Erkul Co-founder & Chief Executive Officer, Kernal Biologics Inc.

Synopsis

  • Improvements in innate immunogenicity of mRNA therapeutics can expand their
    therapeutic window
  • Cancer ribosomes provide a novel opportunity for the design of onco-selective
    mRNAs
  • Stealth, onco-selective, and oncolytic mRNAs can induce tumor regression in
    syngeneic mouse models resistant to check-point inhibitors

9:30 am Next Generation Self-Replicating RNA Vectors to Enable New Approaches to Immunotherapy

  • Nathaniel Wang Chief Executive Officer & Co-Founder, Replicate Bioscience

Synopsis

  • Next generation synthetic srRNA vectors can lower dose by orders of magnitude
    compared to current srRNA designs
  • Developing new srRNA products requires independent optimization of vectors,
    gene inserts, and delivery
  • Improved srRNA bioactivity enable new approaches for immunotherapies in
    oncology

10:00 am Programming mRNA for Cancer Immunotherapy

  • Tasuku Kitada President, Director, Co-founder, Head of Research & Development, Strand Therapeutics Inc.

Synopsis

  • Outlining current preclinical and clinical data indicating efficacy of mRNA cancer
    treatments
  • Discussing why Strand’s approach may be superior to current mRNA drugs in the
    clinic
  • The future of mRNA oncology therapy may involve precise programming of
    protein expression using synthetic biology

10:30 am Morning Networking Break

RNA Translation & Regulatory Consideration for Next Generation RNA Therapeutics

11:30 am Engineering New Modalities to Control RNA Translation

  • Velia Siciliano Principal Investigator - Synthetic & System Biology for Biomedicine, Italian Institute of Technology

Synopsis

  • Use of RNA binding proteins to encode RNA circuits
  • Design of RNA-encoded genetic devices by RBP
  • Re-engineering RBPs to respond to protease as indication of viral infection

12:00 pm Roundtable Discussion: Discussing Regulatory Considerations for Next Generation RNA Therapeutics & Vaccines

1:00 pm Networking Lunch

Emerging & Next Generation Formulation & Delivery Strategies to Maximize Therapeutic Potentials

2:00 pm Unravelling Viral & Non-viral Delivery Approaches for Next Generation RNA Therapeutics

  • Anna Blakney Assistant Professor, University of British Columbia

Synopsis

  • Understanding the stability and quality differences between viral and non-viral
    delivery strategies
  • Better understanding biological mechanism of non-viral delivery strategies to
    improve targeted delivery
  • How to choose the most appropriate delivery system for different types of RNA?

2:30 pm Panel Discussion: Discussing Emerging LNP Modifications & Polymer-Based RNA Delivery for Next Generation RNA Therapeutics

  • Andrew Geall Co-founder & Chief Development Officer, Replicate Bioscience
  • Thomas Colace Director, LNP Formulation, Tessera Therapeutics
  • Allen Horhota Senior Director & Head of Delivery, Orna Therapeutics
  • Anna Blakney Assistant Professor, University of British Columbia

Synopsis

  • Outlining the advantages of different LNP modifications to enhance target specificity of next generation RNA
    therapeutics
  • Describing the biological mechanism of LNP and polymer-based delivery to increase target specificity
  • Discussing the challenges of maintaining sufficient extrahepatic protein expression

3:30 pm Next Generation Nebulizer Formulations for mRNA-Based Therapeutics for the Lung

Synopsis

  • Development of nebulization screening platform for mRNA delivery to the lung
  • Polymer versus LNP for lung delivery via nebulization
  • Demonstration of efficacy against SARS-CoV-2 and influenza

4:00 pm Chair’s Closing Remarks

  • Andrew Geall Co-founder & Chief Development Officer, Replicate Bioscience

End of Next Generation RNA Therapeutics Summit

VIEW FULL EVENT GUIDE
REGISTER